PDF(Pubmed)
Abstract：
UNASSIGNED: This study compared human β-defensin 1 (hBD-1) salivary levels in patients with periodontitis before and after phase I periodontal therapy.
UNASSIGNED: This controlled before-and-after study included 16 patients in the intervention group and 28 participants in the control group. Patients in the intervention group had stage 3 grade B periodontitis with no systemic diseases and had not taken any medications in the last six months. The control group included participants with healthy periodontium. Before and after phase I periodontal therapy, salivary samples were collected from the intervention group. ELISA was used to measure hBD-1 levels.
UNASSIGNED: Salivary levels of hBD-1 decreased after phase I periodontal treatment in periodontitis patients, approaching those in healthy individuals. However, this reduction was not statistically significant (P=0.389). In patients with a probing depth (PD) of at least 3 mm, salivary levels of hBD-1 decreased significantly (P=0.019) following the intervention. There was no significant correlation between changes in hBD-1 levels and clinical indices, such as clinical attachment loss (CAL), probing depth, or bleeding index (BI) (P˃0.05).
UNASSIGNED: The current study demonstrated promising results concerning a probable link between hBD-1 and periodontitis. However, more research with sufficiently large sample sizes and more robust study designs is necessary.
UNASSIGNED: This controlled before-and-after study included 16 patients in the intervention group and 28 participants in the control group. Patients in the intervention group had stage 3 grade B periodontitis with no systemic diseases and had not taken any medications in the last six months. The control group included participants with healthy periodontium. Before and after phase I periodontal therapy, salivary samples were collected from the intervention group. ELISA was used to measure hBD-1 levels.
UNASSIGNED: Salivary levels of hBD-1 decreased after phase I periodontal treatment in periodontitis patients, approaching those in healthy individuals. However, this reduction was not statistically significant (P=0.389). In patients with a probing depth (PD) of at least 3 mm, salivary levels of hBD-1 decreased significantly (P=0.019) following the intervention. There was no significant correlation between changes in hBD-1 levels and clinical indices, such as clinical attachment loss (CAL), probing depth, or bleeding index (BI) (P˃0.05).
UNASSIGNED: The current study demonstrated promising results concerning a probable link between hBD-1 and periodontitis. However, more research with sufficiently large sample sizes and more robust study designs is necessary.
摘要：
■本研究比较了牙周炎患者在I期牙周治疗前后的人β-防御素1（hBD-1）唾液水平。
■这项前后对照研究包括干预组的16名患者和对照组的28名参与者。干预组患者患有3期B级牙周炎，无全身性疾病，最近6个月未服用任何药物。对照组包括健康牙周组织的参与者。一期牙周治疗前后,从干预组收集唾液样本.ELISA用于测量hBD-1水平。
■牙周炎患者在I期牙周治疗后唾液中hBD-1水平下降，接近那些健康的人。然而,这一减少无统计学意义(P=0.389).在探测深度（PD）至少为3毫米的患者中，hBD-1的唾液水平在干预后显著下降(P=0.019)。hBD-1水平变化与临床指标无显著相关性,如临床附着丧失(CAL)，探测深度,或出血指数（BI）（P＜0.05）。
■当前的研究证明了关于hBD-1与牙周炎之间可能存在联系的有希望的结果。然而,更多的研究与足够大的样本量和更强大的研究设计是必要的。
■这项前后对照研究包括干预组的16名患者和对照组的28名参与者。干预组患者患有3期B级牙周炎，无全身性疾病，最近6个月未服用任何药物。对照组包括健康牙周组织的参与者。一期牙周治疗前后,从干预组收集唾液样本.ELISA用于测量hBD-1水平。
■牙周炎患者在I期牙周治疗后唾液中hBD-1水平下降，接近那些健康的人。然而,这一减少无统计学意义(P=0.389).在探测深度（PD）至少为3毫米的患者中，hBD-1的唾液水平在干预后显著下降(P=0.019)。hBD-1水平变化与临床指标无显著相关性,如临床附着丧失(CAL)，探测深度,或出血指数（BI）（P＜0.05）。
■当前的研究证明了关于hBD-1与牙周炎之间可能存在联系的有希望的结果。然而,更多的研究与足够大的样本量和更强大的研究设计是必要的。
